Galectin Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference

NORCROSS, Ga., April 07, 2016 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the Company’s president, chief executive officer and chief medical officer, will present at Needham & Company’s 15^th Annual Healthcare Conference on Wednesday, April 13, 2016 at 3:00 p.m. Eastern time. The conference is being held at the Westin Grand Hotel in New York City on April 12-13, 2016.

A live webcast of the presentation may be accessed on the company’s website at www.galectintherapeutics.com. The webcast and presentation will be archived for 90 days following the event.

About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected].

or

LHA
Kim Golodetz
(212) 838-3777
[email protected] 

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.